Work

Psychedelics, psychiatry and pharmacokinetics - where are we now?

Year: 2025

Type: article

Abstract: 1. Classical psychedelics are gaining attention as potential treatments for a range of neuropsychiatric conditions, including depression, anxiety, and addictions [1]. Psychedelics differ from tradi...

Source: Expert Opinion on Drug Metabolism & Toxicology

DOI: 10.1080/17425255.2025.2549987

Authors: Alice Caulfield, Elliot Hampsey, Allan H. Young

Institutions: King's College London, Hammersmith Hospital, Imperial College London

Language: English

Topic: Psychedelics and Drug Studies

Subfield: Clinical Psychology

Field: Psychology

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Sunovion, Wellcome Trust, LivaNova, Servier, H. Lundbeck A/S, Allergan

Awards: King’s PhD Programme in Mental Health Research for Health Professionals, King’s PhD Programme in Mental Health Research for Health Professionals

OpenAlex ID: W4413289403

FWCI: 2.241

Cites: 19

Cited by: 2

Related to: 10